AB–PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA (Item No. 14038) is an analytical reference material categorized as a cannabinoid.1 AB-PINACA is regulated as a Schedule I compound in the United States. This product is intended for research and forensic applications.
This product is a qualified Reference Material (RM) that has been manufactured and tested to meet ISO17025 and Guide 34 guidelines. These materials are tested using validated analytical methods on qualified instrumentation to ensure traceability of measurements. All traceable RMs may be distinguished by their CofAs and can be downloaded below using the batch number located on the product label. For a representative CofA please contact our technical support.
is a synthetic cannabinoid similar to the natural cannabinoid Tetrahydrocannabinol (THC)
, which shares many of the same chemical properties and is currently enjoying just as much attention from the global research community.
globalresearchemvendor.com – has recently made it possible to purchase AB-PINACA, which can be used as a viable research alternative to much sought-after, but largely illegal natural cannabinoids like THC or dronabinol.
globalresearchemvendor.com provides you with the amazing possibility to buy AB-PINACA in a very pure form from a certified vendor, so that you can make your scientific research with the best available chemical materials.
The chemical formula of AB-PINACA
indicated that the effects of this chemical compound might be very similar of THC
– the active substance of the cannabis plant . Its pharmacology can provide strong interaction with CB1 and CB2 receptors and a possible role as a cannabinoid agonist, which could give the research chemical antidepressant and analgesic properties.
Please note that AB-PINACA
can be studied only under optimal laboratory conditions and that in vivo research involving live organisms is not allowed. AB-PINACA
can be safely stored for up to 2 years on room temperature
Synthetic cannabinoids (SC), are a novel class of designer drugs which emerged as a drug of abuse in the late 2000’s. We report a case series of 6 patients who may have smoked a synthetic cannabinoid product in a remote wilderness setting. They presented with varying degrees of altered mental status, agitation, and seizures. Two were confirmed to have AB-PINACA, ADB-PINACA
and their respective pentanoic acid metabolites in biological specimens via liquid chromatography time-of-flight mass spectrometry (LC-TOF/MS). Both compounds had DEA Schedule I classification at the time of case presentation, and 22 SCs are currently temporary or permanent DEA Schedule I. More than 150 SCs are known to date, and new compounds are appearing at a rapid rate on darknet and surface web e-commerce websites, marketed as “research chemicals” or “legal highs.” The scale and rapidity of SC evolution make legal control and analytical detection difficult. Nontargeted testing with liquid chromatography high resolution mass spectrometry (LC-HRMS), examining both parent compounds and metabolites, is the ideal method for novel SC identification and confirmation. Due to full agonism at the cannabinoid receptors CB1 and CB2, clinical effects are more severe than marijuana, which is a partial cannabinoid receptor agonist. They include agitated delirium, lethargy and coma, seizures, tachycardia, hypertension, and hallucinations, among other findings. Treatment is primarily symptomatic and aimed at airway protection and control of agitation and seizures. SCs do not appear to be abating anytime soon and require the cooperation of law enforcement, analytical scientists, and clinicians to adequately control.